Drug reaction with eosinophilia and systemic symptoms resulting from allopurinol
DOI:
https://doi.org/10.66344/jpad.v34i4.2732Keywords:
Drug reaction with eosinophilia and systemic symptoms, allopurinol, elevated liver enzyme, case reportAbstract
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe drug reaction to the skin that is characterized by fever, lymphadenopathy, hematological abnormalities, involvement of internal organs, and reactivation of the virus. Allopurinol and other drugs are only a few of the medications that have been linked to DRESS. A Male, 42 years old, referred from a regional hospital, with complaints of reddish rash all over the body since 5 days. Physical examination revealed elevated body temperature. dermatologic status appeared to be obvious macules and erythematous patches with fuzzy boundaries, a variety of shapes, a large number, guttate to plaque size, confluent arrangement, and universal distribution in the facial, thorax, upper and lower extremities regions. This complaint arose after the patient took a high dose of allopurinol. Blood laboratory examination revealed eosinophilia, leukocytosis, elevated liver enzymes, and hypoalbuminemia. After treatment with steroid injections and topical creams and discontinuation of previous medications, there was clinical improvement. DRESS is a severe multiorgan hypersensitivity reaction that is mostly caused by a limited number of drugs in patients with a genetic predisposition. Accumulation of oxypurinol, especially in patients with decreased renal clearance, increases the risk of developing DRESS syndrome.
References
1. Jörg L, Helbling A, Yerly D, Pichler WJ. Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS). Clin Transl Allergy. 2020;10(1):1–8.
2. de Groot AC. Patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): A literature review. Contact Dermatitis. 2022;86(6):443–79.
3. Cardones AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clinics Dermatol. 2020;702–11.
4. Stirton H, Shear NH, Dodiuk-Gad RP. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/ Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS. Biomedicines. 2022;10(5):999.
5. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301–8.
6. Heelan K, Sibbald C, Shear NH. Cutaneous Reactions to Drugs. In: Fitzpatrick’s Dermatology. 9th ed. Philadelphia: McGraw Hill Education Medical; 2018. p. 749–64.
7. Aatif T, Fatihi J, El Annaz H, Qamouss O. Allopurinol-induced Drug Reactions with Eosinophilia and Systemic Symptoms Syndrome with Interstitial Nephritis. Indian J Nephrol. 2018;28(6):477–81.
8. Sevinç C, Tosun Taşar P, Büyükkurt E. Approach to DRESS Syndrome Associated with Allopurinol Use in a Geriatric Patient. Eur J Geriatr Gerontol. 2019;1(3):107–11.
9. Tharp MD. Antihistamines. In: Fitzpatrick’s Dermatology. 9th ed. Philadelphia: McGraw Hill Education Medical; 2018. p. 3451–62.
10. Han XD, Koh MJA, Wong SMY. Drug reaction with eosinophilia and systemic symptoms in a cohort of Asian children. Pediatr Dermatol. 2019;36(3):324–9.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Nanda Earlia, Aqil Yuniawan Tasrif, Mikyal Bulqiah, Fitri Dewi Ismida, Mahda Rizki Liana
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
